Covishield single dose 61% effective against delta: Indian Covid panel chief
Skip to main content
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
The Business Standard
FRIDAY, MAY 20, 2022
FRIDAY, MAY 20, 2022
  • Home
  • Economy
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Splash
  • Features
  • Videos
  • Long Read
  • Games
  • Epaper
  • More
    • COVID-19
    • Bangladesh
    • Infograph
    • Interviews
    • Offbeat
    • Thoughts
    • Podcast
    • Quiz
    • Tech
    • Subscribe
    • Archive
    • Trial By Trivia
    • Magazine
    • Supplement
  • বাংলা
Covishield single dose 61% effective against delta: Indian Covid panel chief

Coronavirus chronicle

TBS Report
16 June, 2021, 09:30 pm
Last modified: 16 June, 2021, 09:50 pm

Related News

  • India gives conditional market nod for Covishield and Covaxin
  • India rules out reducing gap between Covishield doses
  • Serum sends 10 lakh Covishield doses after 7-month halt
  • UK recognises Covishield jab after India outcry
  • Contact nearby centres soon for 2nd dose of AstraZeneca: DGHS 

Covishield single dose 61% effective against delta: Indian Covid panel chief

TBS Report
16 June, 2021, 09:30 pm
Last modified: 16 June, 2021, 09:50 pm
A vial of AstraZeneca coronavirus disease (Covid-19) vaccine doses at a facility in Milton, Ontario, Canada, March 3, 2021. REUTERS/Carlos Osorio
A vial of AstraZeneca coronavirus disease (Covid-19) vaccine doses at a facility in Milton, Ontario, Canada, March 3, 2021. REUTERS/Carlos Osorio

Statistically significant data from CMC Vellore based on thousands of cases during the Delta outbreak shown a 61% effectiveness with a single dose of Covishield and 65 per cent with two doses.

The information was revealed by NK Arora, Chairperson of the Indian government's Covid Working Group.

Amid a heated debate on the wide gap India is taking between the first and second dosages of the Covishield vaccine, it has been revealed that data from Indian trials suggest the 12-16 weeks interval was medically sound. In comparison, data from the UK, which has been used to suggest otherwise was statistically less relevant to India, according to Dr Arora.

"When we started with the national Covid immunisation programme...we had an interval of four weeks. That was based on the trial showed that, at a four-week interval, the immune response is very good. Although the UK, at that time, had already increased the interval to 12 weeks. That was the time they were facing the challenge of the Alpha variant outbreak and they were having a tough time in December-January," Dr Arora said, reports the NDTV.

"But we were not convinced and we went ahead with four weeks. Six weeks later the WHO also suggested that 6-8 weeks may be a good idea. We reviewed the data and we had initial experience from the UK and we thought that it may worthwhile to increase it to 6-8 weeks," he said.

However, the working group decided to look at the real-life data coming in from the UK, since that country and India are the largest consumers of the AstraZeneca vaccine -- Covishield in India.

In April, he said, Public Health England, suggested that with a 12-week interval, the vaccine efficacy was varying between 65% to 80%. This was the worst period of the Delta variant outbreak in India.

"We took the decision on 6th or 13th of May, and within two days we learnt that Public Health England had...decided that they showed that, with one dose, the protection is 33%," Dr Arora said.

 

Top News

Covishield

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Infographic: TBS
    Businesses reel under soaring costs
  • Photo: Mumit M/TBS
    What delays infrastructure projects in Bangladesh?
  • What needs to be done now?
    What needs to be done now?

MOST VIEWED

  • Ryu Yong Chol, an official at North Korea's state emergency epidemic prevention headquarters, speaks during a daily coronavirus program on state-run television KRT, in this still image obtained from KRT footage released on May 20, 2022. REUTERS TV/KRT via REUTERS
    North Korea's Dr Fauci? Health official emerges as face of Covid campaign
  • Workers in protective suit spray disinfectant at a community, during the lockdown to curb the spread of the coronavirus disease (COVID-19) in Shanghai, China, April 5, 2022. REUTERS/Aly Song
    Shanghai detects new infections after five days of 'zero Covid'
  • Volunteers carry out temperature screening during an anti-virus campaign in Pyongyang, North Korea in this image released by North Korea's Korean Central News Agency (KCNA) on March 4, 2020. KCNA via REUTERS/File Photo
    North Korea hails 'good results' on Covid as fever cases pass 2 million
  • Medical staff members check the temperature of people as they enter at Capital Airport, following an outbreak of Covid-19, in Beijing, China, 5 November, 2020. Photo: Reuters
    China relaxes some Covid test rules for US, other travellers
  • Representational image.
    China Junshi's potential Covid drug shows promise in small trial
  • A woman wearing protective mask walks at a sidewalk near business district in Jakarta, Indonesia March 2, 2020. REUTERS/Willy Kurniawan/Files
    Indonesia to drop outdoor mask mandate as Covid-19 infections drop

Related News

  • India gives conditional market nod for Covishield and Covaxin
  • India rules out reducing gap between Covishield doses
  • Serum sends 10 lakh Covishield doses after 7-month halt
  • UK recognises Covishield jab after India outcry
  • Contact nearby centres soon for 2nd dose of AstraZeneca: DGHS 

Features

Professor Mustafizur Rahman. Illustration: TBS

Project delays and escalating costs are driven by frequent revisions and lack of good governance

1h | Panorama
Photo: Mumit M/TBS

What delays infrastructure projects in Bangladesh?

1h | Panorama
Foods that you should never put in the refrigerator

Foods that you should never put in the refrigerator

1h | Food
Beef Kunafa: A treat for beef and cheese lovers

Beef Kunafa: A treat for beef and cheese lovers

2h | Food

More Videos from TBS

Gazipur restaurant that serves 150 food items

Gazipur restaurant that serves 150 food items

2h | Videos
How to prepare for a job

How to prepare for a job

3h | Videos
Putin's strategies to face Nato

Putin's strategies to face Nato

15h | Videos
How many countries have nuclear weapons and how many are there?

How many countries have nuclear weapons and how many are there?

15h | Videos

Most Read

1
Tk100 for bike, Tk2,400 for bus to cross Padma Bridge
Bangladesh

Tk100 for bike, Tk2,400 for bus to cross Padma Bridge

2
Representative Photo: Pixabay.
Bangladesh

Microplastics found in 5 local sugar brands

3
Mushfiq Mobarak. Photo: Noor-A-Alam
Panorama

Meet the Yale professor who anchors his research in Bangladesh and scales up interventions globally

4
A packet of US five-dollar bills is inspected at the Bureau of Engraving and Printing in Washington March 26, 2015. REUTERS/Gary Cameron
Banking

Dollar hits Tk100 mark in open market

5
The story of Bangladesh becoming a major bicycle exporter
Industry

The story of Bangladesh becoming a major bicycle exporter

6
PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire
Crime

PK Halder: How a scamster rose from humble beginnings to a Tk11,000cr empire

The Business Standard
Top
  • Home
  • Entertainment
  • Sports
  • About Us
  • Bangladesh
  • International
  • Privacy Policy
  • Comment Policy
  • Contact Us
  • Economy
  • Sitemap
  • RSS

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net

Copyright © 2022 THE BUSINESS STANDARD All rights reserved. Technical Partner: RSI Lab